235 related articles for article (PubMed ID: 22585575)
21. NDRG1 promotes growth of hepatocellular carcinoma cells by directly interacting with GSK-3β and Nur77 to prevent β-catenin degradation.
Lu WJ; Chua MS; Wei W; So SK
Oncotarget; 2015 Oct; 6(30):29847-59. PubMed ID: 26359353
[TBL] [Abstract][Full Text] [Related]
22. Parkin facilitates proteasome inhibitor-induced apoptosis via suppression of NF-κB activity in hepatocellular carcinoma.
Zhang X; Lin C; Song J; Chen H; Chen X; Ren L; Zhou Z; Pan J; Yang Z; Bao W; Ke X; Yang J; Liang Y; Huang H; Tang D; Jiang L; Liu J
Cell Death Dis; 2019 Sep; 10(10):719. PubMed ID: 31558697
[TBL] [Abstract][Full Text] [Related]
23. Deregulated Syk inhibits differentiation and induces growth factor-independent proliferation of pre-B cells.
Wossning T; Herzog S; Köhler F; Meixlsperger S; Kulathu Y; Mittler G; Abe A; Fuchs U; Borkhardt A; Jumaa H
J Exp Med; 2006 Dec; 203(13):2829-40. PubMed ID: 17130299
[TBL] [Abstract][Full Text] [Related]
24. Novel role of apatinib as a multi-target RTK inhibitor in the direct suppression of hepatocellular carcinoma cells.
Li X; Xu A; Li H; Zhang B; Cao B; Huang J
Biochim Biophys Acta Mol Basis Dis; 2018 May; 1864(5 Pt A):1693-1701. PubMed ID: 29486282
[TBL] [Abstract][Full Text] [Related]
25. Combined inhibition of Chk1 and Wee1: in vitro synergistic effect translates to tumor growth inhibition in vivo.
Carrassa L; Chilà R; Lupi M; Ricci F; Celenza C; Mazzoletti M; Broggini M; Damia G
Cell Cycle; 2012 Jul; 11(13):2507-17. PubMed ID: 22713237
[TBL] [Abstract][Full Text] [Related]
26. Signaling of the ITK (interleukin 2-inducible T cell kinase)-SYK (spleen tyrosine kinase) fusion kinase is dependent on adapter SLP-76 and on the adapter function of the kinases SYK and ZAP70.
Hussain A; Mohammad DK; Gustafsson MO; Uslu M; Hamasy A; Nore BF; Mohamed AJ; Smith CI
J Biol Chem; 2013 Mar; 288(10):7338-50. PubMed ID: 23293025
[TBL] [Abstract][Full Text] [Related]
27. Co-expression network analysis identifies Spleen Tyrosine Kinase (SYK) as a candidate oncogenic driver in a subset of small-cell lung cancer.
Udyavar AR; Hoeksema MD; Clark JE; Zou Y; Tang Z; Li Z; Li M; Chen H; Statnikov A; Shyr Y; Liebler DC; Field J; Eisenberg R; Estrada L; Massion PP; Quaranta V
BMC Syst Biol; 2013; 7 Suppl 5(Suppl 5):S1. PubMed ID: 24564859
[TBL] [Abstract][Full Text] [Related]
28. Validation of VX2 as a Hepatocellular Carcinoma Model: Comparison of the Molecular Reaction of VX2 and HepG2 Tumor Cells to Sorafenib In Vitro.
Nass N; Streit S; Wybranski C; Jürgens J; Brauner J; Schulz N; Powerski M; Ricke J; Kalinski T; Dudeck O; Seidensticker M
Anticancer Res; 2017 Jan; 37(1):87-93. PubMed ID: 28011478
[TBL] [Abstract][Full Text] [Related]
29. Glucose deprivation is associated with Chk1 degradation through the ubiquitin-proteasome pathway and effective checkpoint response to replication blocks.
Kim AJ; Kim HJ; Jee HJ; Song N; Kim M; Bae YS; Chung JH; Yun J
Biochim Biophys Acta; 2011 Jun; 1813(6):1230-8. PubMed ID: 21440578
[TBL] [Abstract][Full Text] [Related]
30. Dual Inhibition of Cdc7 and Cdk9 by PHA-767491 Suppresses Hepatocarcinoma Synergistically with 5-Fluorouracil.
Li W; Zhao XL; Shang SQ; Shen HQ; Chen X
Curr Cancer Drug Targets; 2015; 15(3):196-204. PubMed ID: 25643258
[TBL] [Abstract][Full Text] [Related]
31. [Inhibitory effect of full-length spleen tyrosine kinase on invasion and metastasis of human laryngeal squamous cells].
Li Z; Cai Z; Tao B; Jin Q
Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2014 Nov; 49(11):943-9. PubMed ID: 25598376
[TBL] [Abstract][Full Text] [Related]
32. Down-regulation of Rab17 promotes tumourigenic properties of hepatocellular carcinoma cells via Erk pathway.
Qi J; Zhao P; Li F; Guo Y; Cui H; Liu A; Mao H; Zhao Y; Zhang X
Int J Clin Exp Pathol; 2015; 8(5):4963-71. PubMed ID: 26191189
[TBL] [Abstract][Full Text] [Related]
33. Once phosphorylated, tyrosines in carboxyl terminus of protein-tyrosine kinase Syk interact with signaling proteins, including TULA-2, a negative regulator of mast cell degranulation.
de Castro RO; Zhang J; Groves JR; Barbu EA; Siraganian RP
J Biol Chem; 2012 Mar; 287(11):8194-204. PubMed ID: 22267732
[TBL] [Abstract][Full Text] [Related]
34. Treatment with the Chk1 inhibitor Gö6976 enhances cisplatin cytotoxicity in SCLC cells.
Thompson R; Meuth M; Woll P; Zhu Y; Danson S
Int J Oncol; 2012 Jan; 40(1):194-202. PubMed ID: 21894433
[TBL] [Abstract][Full Text] [Related]
35. Knockdown of THOC1 reduces the proliferation of hepatocellular carcinoma and increases the sensitivity to cisplatin.
Cai S; Bai Y; Wang H; Zhao Z; Ding X; Zhang H; Zhang X; Liu Y; Jia Y; Li Y; Chen S; Zhou H; Liu H; Yang C; Sun T
J Exp Clin Cancer Res; 2020 Jul; 39(1):135. PubMed ID: 32669125
[TBL] [Abstract][Full Text] [Related]
36. Increased SYK activity is associated with unfavorable outcome among patients with acute myeloid leukemia.
Boros K; Puissant A; Back M; Alexe G; Bassil CF; Sinha P; Tholouli E; Stegmaier K; Byers RJ; Rodig SJ
Oncotarget; 2015 Sep; 6(28):25575-87. PubMed ID: 26315286
[TBL] [Abstract][Full Text] [Related]
37. c-Jun NH2-terminal kinase pathway is involved in constitutive matrix metalloproteinase-1 expression in a hepatocellular carcinoma-derived cell line.
Sugioka Y; Watanabe T; Inagaki Y; Kushida M; Niioka M; Endo H; Higashiyama R; Okazaki I
Int J Cancer; 2004 May; 109(6):867-74. PubMed ID: 15027120
[TBL] [Abstract][Full Text] [Related]
38. Cisplatin and Procaterol Combination in Gastric Cancer? Targeting Checkpoint Kinase 1 for Cancer Drug Discovery and Repurposing by an Integrated Computational and Experimental Approach.
Giridhara Prema S; Chandrasekaran J; Kanekar S; George M; Prasad TSK; Raju R; Dagamajalu S; Balaya RDA
OMICS; 2024 Jan; 28(1):8-23. PubMed ID: 38190280
[TBL] [Abstract][Full Text] [Related]
39. Proteasome-dependent degradation of Chk1 kinase induced by the topoisomerase II inhibitor R16 contributes to its anticancer activity.
Feng JM; Zhu H; Zhang XW; Ding J; Miao ZH
Cancer Biol Ther; 2008 Nov; 7(11):1726-31. PubMed ID: 18787399
[TBL] [Abstract][Full Text] [Related]
40. Syk-mediated tyrosine phosphorylation of mule promotes TNF-induced JNK activation and cell death.
Lee CK; Yang Y; Chen C; Liu J
Oncogene; 2016 Apr; 35(15):1988-95. PubMed ID: 26212014
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
